The Helsinki-based company developed the first test to measure all four bodily forms of vitamin B3, called NADs, and glutathiones directly from fresh blood in hours to detect vitamin B3 deficiencies and prevent disease.
NADMED has raised €3.5M across 1 funding round from 5 investors, most recently a round in Aug 2024. Based in Helsinki, Finland; active in Healthtech. Data as of 6 Aug 2026.
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2024-08-22 | Other | €3.5M |
| Business Finland,Nordic Science Investments (NSI),private European investors,University of Helsinki Funds,Voima Ventures |
| View deal → |
